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Summary
A number of therapeutic drugs are toxic to the
kidney proximal tubule (PT) and can cause the
renal Fanconi syndrome (FS). The most frequently
implicated drugs are cisplatin, ifosfamide, tenofovir,
sodium valproate and aminoglycoside antibiotics,
and the new oral iron chelator deferasirox has also
recently been associated with FS. The incidence of
full or partial FS is almost certainly under-estimated
due to a lack of appropriate systematic studies, vari-
ations in definitions of tubular dysfunction and
under-reporting of adverse events. The clinical fea-
tures of FS are amino aciduria, low molecular
weight proteinuria, hypophosphataemia, metabolic
acidosis and glycosuria. The most serious complica-
tions are bone demineralization from urinary phos-
phate wasting and progressive decline in kidney
function. Commonly used tests for kidney function
such as estimated glomerular filtration rate and urine
albumin/creatinine ratio are not sensitive markers of
PT toxicity; patients at risk should thus be monitored
with more appropriate tests, and drugs should be
stopped or reduced in dose if toxicity occurs.
Substantial recovery of PT function can occur after
withdrawal of therapy, but this can take months and
chronic damage may persist in some cases.
Introduction
The era of modern medicine has been defined by a
huge expansion in pharmacological therapies for
previously untreatable conditions; unfortunately,
however, some of these drugs can have toxic side
effects in the kidney. The proximal tubule (PT) is the
first part of the kidney tubule after the glomerulus;
many drugs are excreted across the PT and it is the
commonest site of toxicity in the kidney. Impairment
of normal PT function causes urinary wasting of sub-
stances that are predominantly or exclusively re-
absorbed at this site—namely amino acids, low
molecular weight proteins (LMWPs), phosphate, bi-
carbonate, glucose and urate1—and the clinical
features of the Lignac-de Toni-Debre´-Fanconi syn-
drome (usually abbreviated to FS). The PT also re-
absorbs significant amounts of sodium, potassium,
chloride, magnesium and calcium, but alternative
uptake pathways in the distal tubule can compen-
sate for these losses.
There are many different causes of FS, including
hereditary conditions such as cystinosis, mitochon-
drial cytopathy, tyrosinaemia, fructose intolerance,
galactosaemia, Wilson’s disease, Dent’s disease and
Lowe syndrome.1 Drug toxicity is by far the com-
monest cause of acquired FS, and this is a significant
clinical problem that can limit the development and
application of otherwise highly effective therapies.
In specialties such as HIV medicine, the increasing
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availability of highly potent life-long therapies
means that the balance of associated kidney dis-
orders is rapidly shifting from those caused by the
disease to those caused by the drug treatments.
Epidemiology and aetiology
The list of drugs associated with FS continues to
grow (Table 1), with the most frequent causes
being anti-cancer agents, anti-virals and aminogly-
coside antibiotics.2 Many drugs are taken up by the
PT from the blood stream via a range of transporters
expressed at the cell surface membranes (such as
organic cation and anion transporters and p-glyco-
protein3). As a result, intracellular drug concentra-
tions can reach high levels in the PT, which
probably explains why toxicity in this nephron seg-
ment is common. In most cases, the actual inci-
dence of tubular toxicity is unknown and probably
under-estimated, due to a lack of systematic studies
using appropriate markers of tubular dysfunction
and under-reporting of adverse events.
Platinum-containing compounds (cisplatin and
carboplatin) and alkylating agents such as ifosfa-
mide are widely used in the treatment of cancer
and are established PT toxins.4–6 Cisplatin is more
toxic than carboplatin due to its greater uptake into
PT cells. Ifosfamide is structurally related to cyclo-
phosphamide, which is not usually nephrotoxic; the
toxicity of ifosfamide in vivo is due to rapid uptake
into tubular cells via organic cation transporters7
and the subsequent generation of the toxic metab-
olite chloracetaldehyde.4 Cisplatin and ifosfamide
both cause acute PT toxicity, which is often revers-
ible; however, some individuals can develop a
chronic tubulopathy, which persists for many years
and can be progressive. Estimates of the incidence
of acute toxicity vary widely among reported studies
(from 5% to 88% for ifosfamide4), but it is clearly a
common occurrence. The development of chronic
toxicity is highly variable and difficult to predict.
Anti-viral drugs are now a relatively common
cause of FS. Nucleoside reverse transcriptase inhibi-
tors (NRTIs) can cause PT toxicity, but it is observed
more frequently with the nucleotide reverse tran-
scriptase inhibitors (NtRTIs) adefovir, cidofovir and
tenofovir, probably due to the high levels of uptake
of these drugs into PT cells via organic anion trans-
porters.8 While they are undoubtedly highly effect-
ive anti-viral agents, the clinical usage of adefovir
and cidofovir has been limited historically because
of nephrotoxicity, and they are both established
causes of FS.9,10 In contrast, the newer agent teno-
fovir was thought to be less nephrotoxic, and it is
now widely used as first-line therapy for HIV and
Hepatitis B infection. Original safety trials showed
no significant deleterious effect of tenofovir on
serum creatinine and estimated glomerular filtration
rate (eGFR)11; however, numerous cases of FS have
subsequently been reported in patients taking
tenofovir.12,13 Severe toxicity probably only occurs
in <1% of patients,13 but many more have evidence
of a milder tubular defect.14
Aminoglycoside antibiotics are widely used to
treat bacterial infections and are known potent PT
toxins with the following rank order: gentami-
cin > tobramycin > amikacin.15 They are avidly
endocytosed at the PT apical membrane and taken
up into lysosomes, where they exert their toxicity.
The incidence of nephrotoxicity may be as high as
14% according to some older studies,16 but this may
have improved more recently because of changes in
dosing and monitoring strategies.17
Sodium valproate is used to treat epilepsy and
mood disorders, and numerous cases of FS have
Table 1 Causes of drug-induced renal FS
Class Drugs Indications for use
Alkylating agents Ifosfamide Cancer
Aminoglycoside antibiotics Gentamicin, Amikacin Gram-negative bacterial infection
Anti-epileptics Sodium valproate Seizures, bipolar disorder
Anti-protozoals Suramin Trypanosomiasis
Dicarboxylic acids Fumaric acid Psoriasis
Iron chelators Deferasirox Iron overload (e.g. in thalassemia)
NRTIs Didanosine, Stavudine HIV
NtRTIs Tenofovir, Adefovir, Cidofovir HIV, Hepatitis B, CMV
Platinum compounds Cisplatin/carboplatin Cancer
Salicylates Aspirin Analgesia, anti-inflammatory
Tetracycline antibiotics Degraded tetracycline Bacterial infection
Tyrosine kinase inhibitors Imatinib mesylate Chronic myeloid leukaemia
262 A.M. Hall et al.
been reported with this drug, mainly in severely dis-
abled patients,18 while many more patients may
develop sub-clinical PT toxicity.19 Fumaric acid is
used topically as a treatment for psoriasis; it is an
isomer of maleic acid, which is a potent and rapid
cause of experimental FS in rodents,20 and FS has
been described in humans taking fumaric acid.21
Other agents that can cause FS include salicylates,22
the anti-parasitic drug suramin,23 tetracycline anti-
biotics24 and tyrosine kinase inhibitors used in the
treatment of haematological malignancies.25
Deferasirox (Exjade) is a new iron chelator used in
patients with a history of multiple blood transfusions
(e.g. for hereditary anaemias). Unlike the older par-
enteral drug deferoxamine, it is administered once
daily and orally and is thus more convenient for pa-
tients requiring chronic therapy. Nephrotoxicity was
noted in phase three studies of deferasirox,26 and
cases of reversible FS have since been reported.27
Pathogenesis
Adult humans typically filter 180 l of fluid per day
through the kidneys; more than 98% of this has to be
reclaimed before excretion, and the bulk of re-
absorption occurs in the PT. Most solute transport
in the PT is coupled directly, or indirectly, to sodium
transport (Figure 1). Plasma proteins smaller than
albumin (LMWPs) are filtered by the glomerulus
and reabsorbed in the PT via receptor-mediated
endocytosis. PT cells are densely packed with mito-
chondria and are dependent on aerobic metabolism
to generate sufficient ATP to power solute transport.
FS represents a global breakdown of solute trans-
port in the PT, rather than an isolated problem with a
particular transporter. There are many different
causes of FS, and the mechanisms through which
they all converge on a unified phenotype are largely
unknown. Various hypotheses have been proposed
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Figure 1. Solute transport in the renal PT and possible mechanisms in the pathogenesis of the renal FS. The majority of fluid
filtered by the glomerulus (G) is reabsorbed along the PT. Further reabsorption takes place in the loop of Henle (LoH), distal
tubule (DT) and collecting duct (CD). Solutes (S) such as amino acids, phosphate and glucose are co-transported across the
PT apical membrane with Na+, while LMWPs are taken up by receptor-mediated endocytosis into lysosomes (L). Sodium
transport is driven by the basolateral Na+/K+-ATPase, which requires ATP generated by mitochondria (M) located in close
proximity (N=nucleus). A number of toxic drugs (X) can rapidly accumulate into PT cells from the bloodstream via
basolateral transporters and can cause FS. Breakdown of PT solute transport in FS may occur for the following reasons:
(1) abnormal fluidity of the apical membrane, (2) impaired endocytosis and recycling of receptors, (3) abnormal lysosomal
function, (4) depletion of the anti-oxidant glutathione (GSH), (5) mitochondrial toxicity and decreased ATP synthesis, (6)
inhibition of the Na+/K+-ATPase and (7) back-leak of solutes through the paracellular pathway or across the apical
membrane.
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(Figure 1), which may not be mutually exclusive,
however, the majority of the available evidence sug-
gests that an underlying defect in PT cell metabolism
is the main mechanism via which most drugs
cause FS,2 including cisplatin,4 gentamicin,28
ifosfamide,29 salicylate,30 tenofovir12,13 and valpro-
ate.18 Experimental application of mitochondrial
toxins blocks PT solute transport,31 and FS is the
commonest renal presentation of patients with mito-
chondrial cytopathy.32 Furthermore, the presence of
enlarged and dysmorphic mitochondria in the PT is
a typical finding in biopsy specimens from patients
with drug-induced FS (Figure 2).12,13
Clinical features
The characteristic clinical features of FS are listed in
Table 2 and result from urinary wasting of solutes
normally reabsorbed in the PT; some patients only
exhibit some of these features (partial FS—see
below). Phosphate depletion is the most important
clinical aspect of FS, because it leads to skeletal
demineralization and osteomalacia, which can pre-
sent with bone pain, fractures and proximal muscle
weakness. Unfortunately, by the time patients de-
velop symptoms, bone disease is often quite
advanced. Metabolic acidosis in FS is typically
mild, with serum bicarbonate maintained
515mmol/l, as long as distal tubule urinary acidifi-
cation mechanisms are intact. Fluid (water and
sodium) loss leading to symptomatic hypovolaemia
is not a common problem in adults, because of com-
pensatory reabsorption in the distal tubule, but some
patients may report polyuria.
It is important to note that commonly used tests
for chronic kidney disease (CKD), such as creatin-
ine-based eGFR and urine albumin/creatinine ratio,
are predominantly measures of glomerular function
and are not sensitive markers of PT function.14,33,34
Patients exposed to tubular toxic drugs may also
develop glomerular dysfunction, but this is not
always the case, and severe FS can occur in the
absence of an increase in serum creatinine.35
Furthermore, if serum creatinine does rise in FS, it
may be due to impaired tubular secretion, rather
than an actual change in GFR.36 Some patients
with drug-induced FS also exhibit signs of toxicity
in the distal nephron (e.g. hypomagnesaemia and a
urinary concentrating defect).
Diagnosis
The diagnosis of drug-induced FS is usually sug-
gested by a temporal relationship between exposure
to a known PT toxin and the development of
tubulopathy. However, with drugs such as tenofovir,
toxicity can occur months or even years after estab-
lishing patients on treatment.37 Improvement in PT
function after withdrawal of the drug confirms the
diagnosis. Methods used to assess kidney function
in patients at risk of drug-induced FS are listed in
Table 3. Urinary LMWPs such as retinol-binding
protein and beta-2-microglobulin are the most sen-
sitive markers of PT dysfunction and provide a quan-
titative readout of severity.14,38 Comparison with
urinary albumin excretion can help to classify pro-
teinuria as being predominantly of either tubular or
glomerular origin33; however, assays for tubular pro-
teinuria are not available in all hospitals. Urine pro-
tein/creatinine ratio (PCR) does not distinguish the
origin of proteinuria, but is more widely available
and is typically raised in patients with FS.37
Renal tubular handling of phosphate can be eval-
uated by calculating either the fractional excretion
(normal <20%) or the tubular maximal reabsorption
(TmP/GFR, normal >0.8mmol/l),39 from paired spot
plasma and urine samples of phosphate and
creatinine:
 Fractional excretion = (Urinephos Plasmacreat 100)/
(PlasmaphosUrinecreat).
 TmP/GFR=Plasmaphos – (Urinephos Plasmacreat/
Urinecreat).
Alkaline phosphatase is typically increased in pa-
tients with reduced bone mineral density, but it can
also be raised for other reasons (e.g. liver disease).
Renal ultrasound scanning is of limited use in FS,
but may demonstrate non-specific signs of renal
damage such as hyperechogenicity of the paren-
chyma.40 Kidney uptake of the radionuclide tracer
dimercaptosuccinic acid can be decreased as a
result of impaired receptor-mediated endocytosis
of the tracer in the PT.41 Radiological features of
reduced bone mineral density may be seen on
plain X-ray (such as pseudo-fractures) and dual-
energy X-ray absorptiometry, while regions of
increased radionuclide uptake on bone scintigraphy
can be confused with bony metastases.42
In some cases, a renal biopsy is performed to
assess the extent of acute tubular damage and irre-
versible tubulointerstitial scarring (Figure 2). There
are no histological features specific to FS, but the
presence of dysmorphic and swollen mitochondria
in the PT is a common finding on electron micros-
copy in drug-induced FS.12,13 Other causes to con-
sider in the differential diagnosis of acquired FS
include heavy metal exposure (e.g. cadmium,
lead), aristolochic acid (contained in some herbal
remedies) or paraquat poisoning, glue sniffing,
Sjogrens syndrome, mitochondrial cytopathy and
light chain disease (myeloma).1
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Risk factors
In general, drug toxicity in the PT is a dose-related
phenomenon. The concentration of drug that PT
cells are exposed to depends on the blood concen-
tration, which in turn is affected by various param-
eters that are the main identified risk factors for
developing FS (Table 4).4,6,13,43 In spite of the exist-
ence of these established risk factors, for many drugs
the occurrence of nephrotoxicity still remains highly
variable among patients, making it difficult to target
monitoring at specific sub-groups. Underlying gen-
etic polymorphisms in membrane transporters and
other molecules affecting uptake or handling of
drugs in PT cells may play a role in determining
risk of toxicity from drugs such as tenofovir44 and
cisplatin.45 It is important to appreciate that drug
safety trials are often performed in relatively healthy
patients with few baseline risk factors; therefore,
nephrotoxicity may only become apparent when
*
Figure 2. Typical histological features in kidney biopsies from patients with drug-induced renal FS. Top left panel: light
microscopy (20 objective magnification) of haematoxylin and eosin stained tissue from a patient with ifosfamide nephro-
toxicity demonstrating damaged and flattened PTs (arrow), interstitial fibrosis (arrowhead) and a normal glomerulus (asterisk).
Top right panel: higher magnification (60) of Periodic Acid-Schiff Methenamine Silver stained tissue demonstrating prox-
imal tubular damage in more detail, including vacuolization of cells (arrow). Bottom panels: swollen and dysmorphic
mitochondria are a common finding in proximal tubular cells on electron microscopy in patients with nephrotoxicity due
to ifosfamide (left) and tenofovir (right).
Table 2 Clinical features of the renal FS
Amino aciduria
Organic aciduria
Low molecular weight proteinuria
Hypophosphataemia
Normoglycaemic glycosuria
Metabolic acidosis
Hypouricaemia
Hypokalaemia
Polyuria
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drugs are subsequently used in wider and more
varied populations.46
Monitoring of patients at risk
As noted earlier, widely used tests for CKD such as
serum creatinine and eGFR are not sensitive markers
of PT dysfunction. This point has been illustrated by
the story of tenofovir, in which original safety studies
using these parameters reported no evidence of
renal toxicity, but multiple cases of tubular toxicity
were steadily reported over time.46 Therefore, to be
effective, monitoring should be focused on more
appropriate markers, such as tubular proteinuria
(if available), urine PCR, phosphate reabsorption
and glycosuria. The optimum frequency of
monitoring in any given patient will depend on the
specific drug and the extent of baseline risk factors.
Various published guidelines are available, for ex-
ample, The UK Children’s Cancer Study Group
(http://www.cclg.org.uk) recommend that patients
exposed to cisplatin or carboplatin should be
screened for nephrotoxicity (serum creatinine and
magnesium, TmP phosphate) within 6months of
treatment, and within 1 year in the case of ifosfa-
mide, with the frequency of further monitoring de-
pendent on these results (every 5 years if normal).
Meanwhile, the British HIV Association (www.
bhiva.org) recommends that patients starting tenofo-
vir should be monitored every 4weeks in the first
year (and every 3months thereafter) with eGFR,
serum phosphate, urine dipstick (for glycosuria)
and urine PCR.
Prevention and treatment
Given that many drugs are renally excreted, it is
important to accurately establish baseline kidney
function before dosing, particularly with drugs
such as cisplatin and ifosfamide. Estimates of GFR
using serum creatinine-based formulae are less ac-
curate above 60ml/min, so isotopic measurements
are often performed. Dose reductions can be made
with drugs such as tenofovir or gentamicin in
Table 3 Methods for assessing kidney function in patients at risk of drug-induced renal FS
Method Requirements Comments
Serum creatinine/eGFR Single blood sample Measures of glomerular function, not sensitive
markers of tubular function. Mild creatinine
rises may occur due to impaired tubular
secretion.
Isotopic GFR Radio-isotope injection,
multiple blood samples
Accurate measurement of glomerular function.
Fractional excretion or maximal
tubular reabsorption of phosphate
Matched blood and urine
samples of phosphate
and creatinine
Phosphate wasting is an important complication
of FS.
Metabolic acidosis Single blood sample Usually mild, unless distal tubular urinary acid-
ification is also impaired.
Urinary albumin/creatinine ratio Spot urine sample Predominantly a marker of glomerular disease,
not sensitive for proximal tubular dysfunction.
Urinary PCR Spot urine sample Not specific for tubular disease, but typically
increased in FS.
Tubular proteinuria
(e.g. retinol-binding protein)
Spot urine sample The most sensitive marker of PT dysfunction.
Amino aciduria and organic aciduria Spot urine sample Typically increased in FS, but not usually used
for monitoring purposes.
Dipstick glycosuria Spot urine sample Marker of PT dysfunction, but may also be
caused by hyperglycaemia.
Table 4 Risk factors for drug-induced renal FS
Drug dose and duration of therapy
Pre-existing renal impairment
Reduced renal mass (e.g. previous nephrectomy)
Older age or very young
Drug interactions
Low body weight
Volume depletion (e.g. diarrhoea and vomiting)
Underlying pharmaco-genetic factors
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patients with pre-existing CKD. Some nephrotoxic
chemotherapy agents are administered with intra-
venous saline to increase their renal excretion.
Specific drugs can be given, such as amifostine
(a glutathione analogue), to try and prevent toxicity,
but the usefulness of these agents is limited by side
effects.47 Prevention of uptake into the PT by inhib-
ition of drug transporters represents another possible
preventive strategy, for example, probenecid, an in-
hibitor of organic anion transporters, has been used
to prevent cidofovir-induced tubular toxicity in pa-
tients with CMV infection.48
Overall, given that strategies to prevent or treat
drug-induced FS are currently limited, the most pru-
dent approach is to use the minimum possible dose
to achieve a therapeutic effect and to monitor pa-
tients carefully using appropriate markers of PT
function. If a patient develops FS while taking a
nephrotoxic drug it should be stopped immediately;
if this is not possible—for example, if there is no
alternative drug and the clinical situation is life-
threatening—then a dose reduction should be
considered.
In patients with established FS, the main goal of
treatment is to prevent complications arising from
urinary wasting of solutes. Increased renal loss of
amino acids and glucose does not lead to adverse
consequences; however, phosphate depletion
causes bone demineralization, and oral phosphate
supplements and a high phosphate diet can help to
compensate for urinary losses. Hypophosphataemia
is worsened by vitamin D deficiency, so levels
should be checked and supplemented if low.
Activation of 25-OH vitamin D to 1,25-OH vitamin
D requires 1-alpha-hydroxylase; this enzyme is
located in the PT so patients with FS may also re-
quire treatment with alfacalcidol or calcitriol. Bone
loss may be compounded by ovarian toxicity and
premature menopause in female patients exposed
to ifosfamide and cisplatin. Chronic metabolic acid-
osis probably also contributes to bone disease in FS
and is easily corrected with oral sodium
bicarbonate.
Mild tubular toxicity and partial
Fanconi syndrome
FS represents the most severe grade of drug-induced
PT toxicity, short of cell necrosis and acute kidney
injury. Many more patients may develop milder
degrees of toxicity, such as isolated tubular protein-
uria,14 the significance of which is often unclear. In
glomerular kidney diseases, proteinuria (mainly al-
buminuria) is associated with a poor renal outcome;
however, the constituents of tubular proteinuria are
different, and although most patients with hereditary
FS develop progressive renal failure over time there
are rare exceptions to this.49 Tubular phosphate
handling should be assessed in patients with partial
FS, since urinary phosphate wasting can occur even
with a normal serum phosphate level.50 Ultimately,
the decision whether to stop therapy should be fully
discussed with the patient by the prescribing phys-
ician, and will typically depend on the strength of
the indication for treatment, the degree of toxicity
(and whether it is worsening over time) and the
availability of alternative non-nephrotoxic drugs.
Prognosis
The PT has a remarkable capacity to regenerate itself
following an insult, and substantial improvement in
function can occur after drug-induced FS, provided
that the offending agent is withdrawn.4,37 However,
recovery of function can take months and is not
always complete, leaving some patients with re-
sidual tubular defects. Long-term follow-up of pa-
tients exposed to ifosfamide has shown that
tubular dysfunction can persist for at least 10 years
after therapy has stopped, and can worsen over time
in some individuals.4
Conclusions
Nephrotoxic potential does not necessarily preclude
the use of drugs, especially where the benefits of
treatment clearly outweigh the risks; for example,
many lives have been saved by the administration
of gentamicin in severe Gram-negative bacterial
sepsis. However, it is extremely important that doc-
tors using drugs toxic to the PT are aware of this
effect and monitor their patients appropriately. If
significant toxicity occurs, treatment should be with-
drawn before damage becomes severe and irrevers-
ible, and the complications of urinary solute wasting
should be addressed with particular attention paid to
hypophosphataemia and bone health. Although
some risk factors for drug-induced FS have been
highlighted, in many cases it remains unclear why
some patients develop toxicity while others do not,
but pharmacogenomics may play a role and more
research is required in this area. Further work is also
needed to develop new strategies to prevent toxicity
or enhance recovery of damaged tubules, or to for-
mulate less toxic analogues of drugs that retain com-
parable therapeutic efficacy.
As new drugs emerge in the future, it is highly
likely that some will be toxic to the PT and cause
FS; therefore, it is vital that lessons are learned from
past experience, and to be more comprehensive
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screening studies for nephrotoxicity in humans
should include tests of both glomerular and tubular
function.
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